Fox Business - The Power to Prosper
Search Site

Henri Termeer

Sanofi to Buy Genzyme for at Least $20.1B

French drugmaker Sanofi-Aventis SA agreed to buy Genzyme Corp with a sweetened $20.1 billion cash offer, plus payments tied to the success of the U.S. biotech group's drugs, the companies said on Wednesday.The acquisition -- which comes nine months after Sanofi CEO Chris Viehbacher first put the idea to Genzyme's Henri Termeer -- is expected to boost Sanofi's earnings from the first year after completion by giving it a new platform in rare diseases.Sanofi will pay $74 a share in cash and offer a tradable contingent value right, or CVR, whose value will depend on Genzyme's experimental multiple sclerosis drug Lemtrada and production of two other medicines.The deal's announcement, which confirmed what sources with knowledge of the talks had told Reuters on Tuesday, marks the second-biggest in biotech history and will help Sanofi offset declining revenue from drugs that have lost, or are set to lose, patent protection.Sanofi predicted the deal, which is expected to close early in the seco...

Read More

  1. US STOCKS-Futures up as economic worries ease, data on tap

    By Chuck MikolajczakNEW YORK (Reuters) - U.S. stock index futures rose Wednesday as new signs of growth in China and Australia eased concerns about the global econom...

  2. US STOCKS-Futures rise as economy concerns ease, data on tap

    By Chuck MikolajczakNEW YORK (Reuters) - U.S. stock index futures rose Wednesday as new signs of growth in China and Australia eased concerns about the global econom...

  3. Wall Street futures signal higher open; data eyed

    * Futures for the Dow Jones industrial average, the S&P 500 and the Nasdaq 100 rise 0.3 to 0.7 percent, pointing to a firmer start on Wall Street on Wednesday.* Auto...

  1. Sanofi, Genzyme In Due Diligence Pact, Talks Go On

    Sanofi-Aventis (SNY) and its takeover target Genzyme (GENZ) Monday signed a confidentiality pact that allows the French drug maker to examine the U.S.-based biotech'...

  2. Genzyme Opens Books to Sanofi in Merger Talks

    U.S. biotechnology company Genzyme Corp and Sanofi-Aventis have executed a nondisclosure agreement, effectively giving the French company the ability to examine Genz...

  3. Sanofi Extends Genzyme Bid Again as Talks Continue

    French drugmaker Sanofi-Aventis extended its $18.5 billion tender offer for U.S. biotech Genzyme (NASDAQ:GENZ) on Monday for a second time, as the companies continue...

  4. Sanofi Extends $18.5 Billion Genzyme Offer to January 21

    Sanofi-Aventis has extended its snubbed $18.5 billion cash bid for U.S. biotech group Genzyme (GENZ.O) by six weeks, buying the French drugmaker time to persuade its...

  5. Genzyme open to Campath clause in Sanofi bid: report

    PARIS (Reuters) - U.S. biotech Genzyme <GENZ.O>, the target of an $18.5 billion takeover bid by French drugmaker Sanofi-Aventis <SASY.PA>, is open to linking the per...

  6. Sanofi-Aventis Goes Hostile With Genzyme Bid

    PARIS -(Dow Jones)- French pharmaceutical giant Sanofi-Aventis S.A. ( SNY ) Monday sought to move forward with its attempt to buy Genzyme Corporation ( GENZ ) by goi...

  7. US STOCKS-Wall St set for higher open on China, Australia data

    By Chuck MikolajczakNEW YORK (Reuters) - Wall Street was set for a higher open Wednesday as new signs of growth in China and Australia eased concerns about the globa...

Freebase CC-BY
Source: Henri Termeer on Freebase, licensed under CC-BY
Other content from Wikipedia, licensed under the GFDL